Opus Genetics gets up to $2M non-dilutive funding from RD Fund for MERTK gene therapy program

Opus Genetics, Inc.

Up to $2 million non-dilutive funding from RD Fund (Foundation Fighting Blindness) for OPGx-MERTK preclinical program.
OPGx-MERTK targets retinitis pigmentosa caused by MERTK gene mutations; no approved therapies exist.
Funding expected to support IND-enabling studies and advance gene therapy pipeline for inherited retinal diseases.
Cash runway extended into second half of fiscal year 2026, based on current projections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.